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OBJECTIVES: Cost-effectiveness estimates for new drugs are
generally derived from limited data on product efﬁcacy and likely
treatment patterns. We evaluated the base-case cost-effectiveness,
from a US perspective, of ritonavir-boosted darunavir
(TMC114/r; darunavir/r), a novel protease inhibitor, plus an
optimized background regimen (OBR) compared with currently
available protease inhibitors plus OBR, for treating HIV infec-
tion in treatment-experienced adults. We then subjected these
estimates to sensitivity and variability analyses, to assess the
effects of uncertainty in the base-case estimates. METHODS: A
Markov model with 3-month cycles was developed to follow
patients through six health states deﬁned by CD4+ cell-count
ranges. Transition probabilities were calculated from clinical
trial data. Cost (2005 US dollars), utility, and mortality data
were estimated from published US sources. The 5-year incre-
mental cost-effectiveness ratio (ICER) was calculated for the base
case. The base case was tested with one-way and probabilistic
sensitivity analyses (PSA) as well as for alternative practice pat-
terns, population and model characteristics (variability analyses).
RESULTS: The base-case 5-year ICER for darunavir/r was
$4657/QALY. The one-way sensitivity analysis results ranged
from −$12,086/QALY (darunavir/r is dominant) to
+$24,899/QALY. Results were most sensitive to uncertainty
about durations of CD4+ increase and stability, rates of CD4+
change, and non-antiretroviral health care costs. By PSA, the
probability of the ICER being below the commonly accepted
threshold of $50,000/QALY was 95.5%. The variability analy-
sis resulted in ICERs between −$42,029 (darunavir/r is domi-
nant) and +$33,625. The lower bound occurred when tipranavir
was the assumed comparator, while the upper bound occurred
when the model time horizon was extended to lifetime. CON-
CLUSION: The impact of parameter uncertainty assessed by sen-
sitivity analysis on the estimated ICER was less than the impact
of variability. Each type of analysis contributes to a fuller under-
standing of the uncertainty in base-case cost-effectiveness 
estimates. After analyses of uncertainty, darunavir/r remains
cost-effective.
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OBJECTIVES: Medicament prices restrict the population access
to antiretroviral therapy in developing countries. International
comparisons indicate Colombia is paying higher ARV prices than
comparative developing countries. In addition, its health system
is highly decentralized due to the large number of institutional
buyers. This study addresses the effectiveness of the price control
regulatory strategy to lower ARV prices and access to therapy.
METHODS: A cross sectional study was performed through a
survey designed for the universe of institutional ARV buyers
(2005). This included insurers and hospitals linked to the Colom-
bian Health and Social Security System. The survey asked infor-
mation about VIH/AIDS infected population, individual ARV
medicaments transactions, prices, discounts and procurement
processes. Descriptive statistics and a multivariate economic
model were performed. The answer rate covered over 87% of
Colombian population. RESULTS: Study results accounted up to
20,697 persons HIV infected. A 79.8% treatment rate was
obtained. Signiﬁcant differences in the infection rate between
both social insurance schemes were identiﬁed: Contributive
insurance population had a 2.7 higher infection probability than
those in the subsidized plan. The lineal regression model showed
no signiﬁcant relationship between the size of the insurance pool
and antiretroviral ﬁnal price to the buyer. Also, there were no
price differences between direct purchases to manufacturers and
those to distributors. There was a monopolistic tendency with
45% of medicaments offered by a single manufacturer. A market
concentration index (Hirsmann-Herﬁndahl) show that 55% of
medicaments purchased in oligopolistic settings. There were no
signiﬁcant price differences from brand-name medicaments and
generic drugs in 12 up to 14 ARV medicaments. Finally, there
were no signiﬁcant relation between the regulated price and
actual institutional prices. CONCLUSION: Colombia should
diversify its regulatory mechanisms and incentives to assure com-
petitiveness, and scale economies in antiretroviral purchases.
This approach should face prospective strategies to compensate
institutional market fragmentation.
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OBJECTIVES: Patients receiving mechanical ventilation are at
an increased risk of pneumonia, which can prolong hospital stays
and increase costs. There are limited national data on the costs
of ventilator-associated pneumonia (VAP) due to Staphylococcus
aureus, a common hospital-acquired pathogen. METHODS:
This retrospective cohort study used data from the 2004 Health
care Cost and Utilization Project Nationwide Inpatient Sample
(HCUP-NIS). Ventilator-dependent patients with S. aureus pneu-
monia were identiﬁed based on ICD-9-CM diagnosis and pro-
cedure codes and compared to ventilator-dependent patients
without a diagnosis of pneumonia. Excess length of stay (LOS)
and costs were estimated. Multivariate models were used to
adjust costs for potential confounding factors, including age,
gender, mortality, hospital region, and comorbidity. RESULTS:
We identiﬁed 198,269 hospitalized patients who required use of
a ventilator, of whom 9592 (4.8%) were identiﬁed as having S.
aureus pneumonia. Patients with VAP due to S. aureus were older
(mean age 62 years vs. 49 years for the comparison group) and
were more likely to have congestive heart failure, chronic pul-
monary disease, diabetes and bacteremia/septicemia. Relative to
the comparison group, patients with VAP due to S. aureus had
signiﬁcantly (P < 0.001) longer mean length of stay (25.6 vs. 14.5
days) and substantially higher average costs per stay ($72,820
vs. $40,171). After controlling for potentially confounding
factors, the excess costs associated with VAP due to S. aureus
were estimated to be approximately $14,000. CONCLUSION:
Our ﬁndings suggest that the economic burden of ventilator-
associated pneumonia (VAP) due to Staphylococcus aureus
